Third Arc Bio is a clinical-stage biotechnology company developing next-generation multifunctional antibodies designed to precisely activate or inhibit T cells across oncology and immunology & inflammation (I&I) diseases. Through its ARCStim and ARCTag platforms, the company aims to harness the power of immune synapses and deliver targeted immune modulation directly to sites of disease, with the potential to improve efficacy and safety.